Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19066754 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 18906805 | METHOD FOR CONVERTING ATRIAL FIBRILLATION TO SINUS RHYTHM WITH LOW-RISK, LOW-COST PROTOCOL, AND PREVENTING RECURRENCE OF ATRIAL FIBRILLATION | October 2024 | October 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18903882 | INJECTABLE FORMULATIONS OF PARP INHIBITORS AND USES THEREOF | October 2024 | May 2025 | Allow | 7 | 2 | 1 | Yes | No |
| 18673805 | EMBOLIC COMPOSITIONS AND METHODS | May 2024 | March 2025 | Allow | 10 | 1 | 1 | No | No |
| 18673814 | EMBOLIC COMPOSITIONS AND METHODS | May 2024 | March 2025 | Allow | 10 | 1 | 1 | No | No |
| 18648498 | COMPOSITE ANTIBACTERIAL HYDROGEL DRESSING, PREPARATION METHOD AND APPLICATION THEREOF | April 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18625862 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | April 2024 | December 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18624706 | POLYOLS AND POLYOL-BASED HYDROGELS WITH ANTI-CANCER ACTIVITY | April 2024 | March 2025 | Allow | 11 | 3 | 1 | No | No |
| 18615185 | LIQUID DOSAGE FORMS OF SODIUM NAPROXEN | March 2024 | March 2026 | Abandon | 24 | 0 | 1 | No | No |
| 18408490 | MODIFIED RELEASE NICORANDIL COMPOUND FORMULATIONS | January 2024 | December 2024 | Abandon | 12 | 0 | 1 | No | No |
| 18567702 | CARBOXYLIC ACID LOADED SALT CARRIER AND THE METHOD FOR PRODUCING THEREOF | December 2023 | September 2025 | Allow | 21 | 2 | 1 | No | No |
| 18527781 | HYDROCOLLOID-BASED SKIN PATCH | December 2023 | July 2025 | Abandon | 20 | 2 | 1 | No | No |
| 18526225 | Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile | December 2023 | August 2024 | Allow | 9 | 0 | 0 | No | No |
| 18513856 | STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION | November 2023 | February 2026 | Allow | 27 | 2 | 1 | No | No |
| 18374645 | COMPOSITIONS COMPRISING A THERMOREVERSIBLE HYDROGEL, AND HAVING AN EXTENDED IN-USE PERIOD | September 2023 | July 2024 | Abandon | 10 | 0 | 1 | No | No |
| 18354636 | Hydrogel Particle Encapsulated Viable Cells for In Vivo Regenerative Treatment | July 2023 | December 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 18129508 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | March 2023 | May 2024 | Abandon | 14 | 1 | 1 | No | No |
| 18129543 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | March 2023 | March 2024 | Abandon | 11 | 0 | 1 | No | No |
| 18129497 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | March 2023 | November 2024 | Abandon | 19 | 2 | 1 | No | No |
| 18187248 | METHOD OF IMAGING | March 2023 | June 2025 | Allow | 27 | 3 | 1 | Yes | No |
| 18187244 | METHOD OF MANUFACTURING AN EMBOLIZING AGENT PRECURSOR | March 2023 | December 2024 | Abandon | 21 | 2 | 1 | Yes | No |
| 18187264 | METHOD OF USING HIGH-FREQUENCY SOUND WAVES | March 2023 | June 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 18187413 | EMBOLIZING AGENT PRECURSOR PHARMACEUTICAL COMPOSITION | March 2023 | May 2024 | Abandon | 14 | 1 | 1 | No | No |
| 18118212 | TOPICAL ANALGESIC GEL COMPOSITIONS | March 2023 | November 2025 | Allow | 32 | 2 | 0 | No | No |
| 18118472 | METHOD FOR PRODUCING ORGANIC MATERIAL MICROPARTICLES, AND METHOD FOR MODIFYING ORGANIC MATERIAL MICROPARTICLES | March 2023 | February 2026 | Abandon | 36 | 3 | 0 | No | No |
| 18040585 | BACTROCERA OLEAE ATTRACTANT COMPOSITION AND USES THEREOF | February 2023 | June 2025 | Allow | 28 | 1 | 1 | No | No |
| 18159860 | PHOTOTHERMAL NANOSTRUCTURES IN TUMOR THERAPY | January 2023 | May 2025 | Abandon | 28 | 2 | 0 | Yes | No |
| 18094673 | MEDICAL DEVICE FOR DELIVERY OF LIFTING AGENT | January 2023 | May 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18093554 | LIPID EMULSIONS AND USES THEREOF | January 2023 | February 2026 | Allow | 37 | 5 | 1 | Yes | Yes |
| 18086412 | Improved Supraparticles | December 2022 | May 2025 | Abandon | 28 | 2 | 1 | Yes | No |
| 18085372 | SOLID ORAL COMPOSITION CONTAINING DYES FOR USE IN ENDOSCOPIC DIAGNOSIS | December 2022 | May 2025 | Abandon | 29 | 2 | 1 | No | No |
| 17999969 | APPLICATION OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING DISEASE RELATED TO THYROIDECTOMY | November 2022 | February 2026 | Allow | 39 | 1 | 0 | No | No |
| 17997347 | METHOD FOR DECOMPOSING COMPOUND AND COMPOUND | October 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17930169 | PULSATILE DRUG DELIVERY SYSTEM FOR TREATING MORNING AKINESIA | September 2022 | September 2025 | Abandon | 36 | 2 | 1 | Yes | Yes |
| 17821680 | STARCH-FREE SOFT CHEW FOR VETERINARY APPLICATIONS | August 2022 | March 2023 | Allow | 7 | 1 | 0 | No | No |
| 17751924 | COMPOSITIONS AND ARTICLES COMPRISING (NANO)DIAMOND PARTICLES | May 2022 | August 2025 | Abandon | 39 | 4 | 1 | No | Yes |
| 17745428 | Dry Powder Formulations for Messenger RNA | May 2022 | December 2025 | Allow | 43 | 3 | 1 | No | No |
| 17727680 | TREATMENTS FOR BENIGN PROSTATIC HYPERPLASIA | April 2022 | December 2023 | Allow | 20 | 3 | 1 | Yes | No |
| 17722986 | WOUND DRESSING COMPRISING AN ANTIMICROBIAL COMPOSITION | April 2022 | August 2025 | Allow | 40 | 3 | 1 | No | No |
| 17723013 | SILICONE-BASED ENTERIC CT CONTRAST MATERIAL | April 2022 | August 2025 | Allow | 40 | 2 | 1 | Yes | Yes |
| 17715491 | STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION | April 2022 | August 2023 | Allow | 17 | 2 | 1 | Yes | No |
| 17634764 | ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS-I LIKE PROTEIN (OMCP) FOR TREATMENT OF AUTOIMMUNE DISEASE | February 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17632568 | PERIVASCULAR LYSATES AND USES THEREOF | February 2022 | November 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17625705 | MULTIVESICULAR LIPOSOME FORMULATIONS OF DEXMEDETOMIDINE | January 2022 | February 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17569720 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | January 2022 | November 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17566882 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | December 2021 | January 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17539445 | MEDICAL DEVICE FOR DELIVERY OF INJECTABLE GEL AND METHODS OF FORMING SAME | December 2021 | October 2025 | Abandon | 47 | 2 | 1 | No | Yes |
| 17520800 | TOPICAL DOXYCYCLINE HYDROGEL WITH IMPROVED LONG-TERM STABILITY | November 2021 | February 2022 | Allow | 3 | 0 | 0 | No | No |
| 17506051 | Medical Device for Delivery of Lifting Agent | October 2021 | March 2023 | Abandon | 17 | 2 | 1 | No | No |
| 17604659 | HYDROGEL DRUG DELIVERY COMPOSITION | October 2021 | May 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17492328 | PATIENT SELECTION METHOD FOR INFLAMMATION | October 2021 | February 2026 | Abandon | 53 | 3 | 1 | No | No |
| 17489982 | MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USE | September 2021 | October 2023 | Allow | 25 | 2 | 0 | No | Yes |
| 17599379 | TARGETING COMPOUNDS FOR CANCERS SELECTED FROM ESOPHAGUS, PHARYNX AND LARYNX, LUNG, BRAIN, AND INTESTINES | September 2021 | June 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17473590 | ENCAPSULATED GAS OR PARTIAL VACUUM CT CONTRAST MATERIAL | September 2021 | September 2024 | Allow | 36 | 2 | 1 | Yes | Yes |
| 17472541 | CHLOROQUINE GEL AND PREPARATION METHOD AND APPLICATION THEREOF | September 2021 | December 2022 | Allow | 15 | 0 | 0 | No | No |
| 17469012 | TOPICAL COMPOSITIONS AND METHODS OF USE | September 2021 | September 2025 | Allow | 48 | 4 | 1 | Yes | No |
| 17433736 | DYNAMIC COVALENTLY LINKED HYDROGELS AS STABILIZATION NETWORK PLATFORMS | August 2021 | January 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17412231 | Therapeutic Medical Device and Methods of Use | August 2021 | December 2023 | Abandon | 27 | 2 | 1 | No | No |
| 17433267 | OPTICALLY HEAT-GENERATING COMPOSITE MATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION | August 2021 | March 2026 | Abandon | 54 | 2 | 1 | No | No |
| 17431405 | HIGH YIELD PRODUCTION OF MICROBUBBLES | August 2021 | February 2026 | Abandon | 54 | 2 | 1 | No | No |
| 17401589 | COMPOSITIONS AND THERAPIES USING NANODIAMONDS SUSPENDED IN A CARRIER | August 2021 | June 2024 | Allow | 34 | 0 | 1 | Yes | No |
| 17430683 | CT CONTRAST AGENT FOR DETECTION OF CACHEXIA | August 2021 | June 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17389936 | INVISIBLE SINGLET FILM | July 2021 | December 2023 | Abandon | 29 | 3 | 1 | No | No |
| 17425699 | CONTRAST SOLUTION FOR THE CHARACTERISATION OF BIOLOGICAL SAMPLES BY ELECTRON OR CORRELATIVE MICROSCOPY | July 2021 | October 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17425430 | SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF | July 2021 | November 2025 | Allow | 51 | 2 | 1 | No | No |
| 17424616 | ALBUMIN NANOPARTICLES, THE MAKING METHOD, AND USES THEREOF | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17374564 | LIQUID DOSAGE FORMS OF SODIUM NAPROXEN | July 2021 | April 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17418704 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | June 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17418120 | Methods for Imaging and Treatment of Somatostatin-Receptor Positive Tumors | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17413923 | TERNARY MICELLAR COMPLEX COMPOSED OF A SIALOGLYCOSPHINGOLIPID, A THERAPEUTICALLY ACTIVE SUBSTANCE AND AN ANTIBODY | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17342945 | EMBOLIC COMPOSITIONS AND METHODS | June 2021 | April 2024 | Allow | 34 | 2 | 1 | Yes | Yes |
| 17296187 | Self-Assembled Microcapsules With Stimuli-Responsive Organic Ligands | May 2021 | November 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17325290 | THERMOSENSITIVE HYDROGEL FOR CANCER THERAPEUTICS AND METHODS OF PREPARATION THEREOF | May 2021 | December 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17302917 | ULTRASOUND MEDIATED DELIVERY OF DRUGS | May 2021 | May 2025 | Allow | 48 | 4 | 1 | Yes | Yes |
| 17313136 | COMPOSITIONS COMPRISING TAPINAROF FOR THE TREATMENT OF PRURITIS | May 2021 | June 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17291996 | METAL OXIDES NANOPARTICLES CONJUGATED WITH NAPHTHALENE DERIVATIVES AS CONTRAST AGENTS FOR THE DETECTION OF BETA AMYLOID PLAQUES BY MAGNETIC RESONANCE IMAGES | May 2021 | March 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17246852 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | May 2021 | June 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17306482 | Implantable Embolic Scaffolds That Promote Healing | May 2021 | October 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17287692 | MARKING PRECURSOR WITH SQUARIC ACID COUPLING | April 2021 | April 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17227024 | COMBINATION THERAPY FOR TREATING METASTATIC PROSTATE CANCER | April 2021 | May 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17280735 | METHOD FOR OBTAINING CONDITIONED FISH MODELS | March 2021 | June 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17279504 | Imaging Agents and Methods of Use | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17207226 | Methods, Systems and Apparatus for Reducing Pathogen Loads in Circulating Body Fluids | March 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17206979 | METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGING | March 2021 | October 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17272607 | POROUS BIORESORBABLE RADIOPAQUE EMBOLIC MICROSPHERES FOR DRUG DELIVERY | March 2021 | February 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17270268 | METHOD FOR PREPARING GADOBUTROL | February 2021 | October 2024 | Allow | 44 | 1 | 0 | No | No |
| 17269094 | PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS | February 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17267788 | MEDICAL HYDROGEL | February 2021 | June 2025 | Abandon | 52 | 4 | 1 | No | No |
| 17266922 | METHODS FOR DISEASE TREATMENT AND DRUG DISCOVERY | February 2021 | August 2025 | Allow | 55 | 1 | 1 | No | No |
| 17266190 | CONJUGATE OF BIOTIN-MODIFIED DIMER AND PHTHALOCYANINE DYE | February 2021 | June 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17266549 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | February 2021 | August 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17264716 | DENDRITIC NANOGEL CARRIERS AND METHOD OF PRODUCTION | January 2021 | February 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17160265 | OIL-FREE AND FAT-FREE AQUEOUS SUSPENSIONS OF CYCLOSPORIN | January 2021 | December 2021 | Abandon | 10 | 0 | 1 | No | No |
| 17160252 | Method of treating ophthalmic conditions | January 2021 | June 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17160258 | METHOD OF TREATING OPHTHALMIC CONDITIONS | January 2021 | June 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17160261 | METHOD OF TREATING OPHTHALMIC CONDITIONS | January 2021 | June 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17160264 | METHOD OF TREATING OPHTHALMIC CONDITIONS | January 2021 | June 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17160272 | METHOD OF TREATING OPHTHALMIC CONDITIONS | January 2021 | June 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17160270 | OIL-FREE AND FAT-FREE AQUEOUS SUSPENSIONS OF CYCLOSPORIN | January 2021 | January 2022 | Abandon | 11 | 0 | 1 | No | No |
| 17152649 | METHOD OF TREATING OPHTHALMIC CONDITIONS | January 2021 | October 2021 | Abandon | 9 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VU, JAKE MINH.
With a 29.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VU, JAKE MINH works in Art Unit 1618 and has examined 953 patent applications in our dataset. With an allowance rate of 35.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner VU, JAKE MINH's allowance rate of 35.8% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by VU, JAKE MINH receive 2.81 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by VU, JAKE MINH is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +34.9% benefit to allowance rate for applications examined by VU, JAKE MINH. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 9.9% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.8% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 53.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 47% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 46.9% of appeals filed. This is in the 12% percentile among all examiners. Of these withdrawals, 49.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 60.8% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.3% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.